newsfilter
← Earnings
Earnings Releases·

Kyntra Bio — Third Quarter 2026 Earnings Summary

Kyntra Bio reported a net income of $0.2 million for the third quarter of 2026, driven by a $14 million gain from restructuring a royalty financing agreement that reduced future payment obligations by $60 million. The company decided to discontinue development of its FG-3246 and FG-3180 programs in metastatic castration-resistant prostate cancer following insufficient efficacy, a move expected to save over $20 million in operating expenses during 2027 and 2028. With $44.1 million in cash and equivalents as of September 30, 2026, Kyntra Bio projects a cash runway extending into 2028 while preparing to initiate a pivotal Phase 3 trial for roxadustat in LR-MDS patients in the first quarter of 2027, contingent on securing a strategic partnership or external capital.

Company
KYNTRA BIO INC
Sector
Healthcare
Industry
Biotechnology